We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sony Invests Millions in Medical Devices and Clinical Pathology

By LabMedica International staff writers
Posted on 18 May 2012
The Israeli business daily Globes (Israel) reported that Sony Corporation (New York, NY, USA) is actively seeking to invest hundreds of millions of dollars in Israeli medical technologies. The consumer electronics company wants to create patient-friendly medical devices and diagnostic kits that will be used in point-of-care settings.

Sony is preparing for a major expansion into the world of medical devices, with a particular interest in medical laboratory testing and diagnostic test kits. Experts regard Sony’s new strategy as a sign that prospects in diagnostic testing remain strong.

This is a major strategy change for Sony. Company officials state that Sony will rely less on consumer electronics as it shifts its focus to healthcare sectors, in an effort to revive earnings

Sony is interested in the attractive business prospects for moving into healthcare. “As populations age, demand for medical devices rises, and we intend to participate in this,” declared Hiroshi Yoshioka, vice president, Sony, Inc., in the Globes article. The Globes story serves to demonstrate how the boundaries between consumer electronics and medical devices are blurring.

Recently, Sony applied for a patent that would use a wristband to monitor the heart rate, vital signs, and blood glucose levels of the wearer. This information would be transmitted to a compatible HDTV where the user could see this data. This would be transmitted to medical personnel if necessary.

The techno Website Engadget posted a news story about how Sony is combining medical device functions with consumer electronics. Pathologists and clinical laboratory managers will find the functions of Sony's patent to be very relevant to their work.

Sony is the latest corporate giant to recognize that it can benefit from the confluence of the fields of biotechnology, medical devices, high tech electronics, information technology, and telecommunications. These various technologies are being combined to create “smart” medical devices, according to BioDFW (Dallas, TX, USA, a life sciences regional alliance.

Related Links:

Globes
Sony Corporation
BioDFW

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Manual Pipetting Aid
Pipette Controllers macro

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM